Citation

Doǧan FS, Onur OE, Altinok AD, Güneysel O. J. Pharmacol. Pharmacother. 2012; 3(4): 333-335.

Copyright

(Copyright © 2012, Medknow Publications)

DOI

10.4103/0976-500X.103694

PMID

unavailable

Abstract

Insulin glargine is a long acting novel recombinant human insulin analogue indicated to improve glycemic control, in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. The time course of action of insulins including insulin glargine may vary between individuals and/or within the same individual. Insulin glargine is given as a 24-h dosing regimen and has no documented half-life or peak effect. Hypoglycemia is the most common adverse effect of insulin, including insulin glargine. As with all insulins, the timing of hypoglycemia may differ among various insulin formulations. We present a case of a 76-year-old male insulin-dependent diabetic patient with refractory hypoglycemia secondary to an intentional overdose of insulin glargine. We would like to highlight the necessity of prolonging IV glucose infusion, for a much longer period than expected from pharmacokinetic properties of these insulin analogues after intentional massive overdose.

Language: en

Keywords

human; male; aged; case report; suicide attempt; overdose; drug overdose; Hypoglycemia; insulin glargine; article; tachycardia; patient monitoring; physical examination; panic; potassium chloride; hypertension; glucose blood level; glucose; hypoglycemia; potassium; potassium blood level; Parkinson disease; diaphoresis; insulin dependent diabetes mellitus; losartan; continuous infusion; piracetam; carbidopa plus entacapone plus levodopa; Insulin glargine; lantus; suicide attempted